Kevin Kevork Niksarli, MD has Just Announced the Launch of Allergan's Exciting New Product Latisse, for Stimulating Eyelash Growth

Share Article

Kevin Kevork Niksarli, MD says that the FDA has approved Latisse as the first drug to promote eyelash growth, according to Allergan, the company that makes Latisse.

Latisse, which will be available by prescription only contains the active ingredient of the glaucoma drug Lumigan, which is also made by Allergan says Kevin Kevork Niksarli, MD.

Dr. Kevin Niksarli also says that eyelash growth is a known side effect of Lumigan, but Lumigan and Latisse are used differently. Lumigan is an eye drop, and Latisse gets dabbed along the lash line on the upper eyelids to promote longer, thicker, lusher lashes.

Allergan states that "Latisse users can expect to experience longer, fuller, and darker eyelashes in as little as eight weeks, with full results in 16 weeks." But Dr. Kevin Niksarli states that if Latisse is stopped, eyelashes will gradually return to their previous appearance as new eyelashes grow in.

Allergan also notes that Latisse may cause darkening of the eyelid skin, which may be reversible, and it "may also cause increased brown pigmentation of the colored part of the eye, which is likely to be permanent."

Some side effects of Latisse may also promote hair growth in other skin areas that it frequently touches, so Allergan recommends blotting it off any skin other than the upper eyelid's lash line to prevent this side effect.

According to Kevin Niksarli, M.D., Latisse was well-tolerated in its clinical trials, with the most common side effects being eye redness, itchy eyes, and skin hyperpigmentation.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kevork Niksarli

212 759 7500
Email >